| Title | Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report |
| Authors | Wu, Shuling Bi, Xiaoyue Lin, Yanjie Yang, Liu Li, Minghui Xie, Yao |
| Affiliation | Capital Med Univ, Beijing Ditan Hosp, Dept Hepatol Div 2, 8 Jingshun East St, Beijing 100015, Peoples R China Peking Univ, Ditan Teaching Hosp, Dept Hepatol Div 2, 8 Jingshun East St, Beijing 100015, Peoples R China |
| Keywords | CEFOPERAZONE-SULBACTAM |
| Issue Date | 16-Jun-2022 |
| Publisher | INFECTIOUS AGENTS AND CANCER |
| Abstract | Cefminox sodium is an antimicrobial agent with broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. Cefminox sodium has high security in clinical practice for its few adverse effects such as coagulation dysfunction, which is rare in clinical treatment. Even in patients suffering from chronic liver disease with coagulation dysfunction, it rarely leads to further deterioration of coagulation function. Therefore, patients with chronic liver disease develop severe coagulation dysfunction during the application of cefminox sodium, which is often mistaken for worsening of liver disease other than considered to be the side effect of the drug. Therefore, we report a 55-year-old female patient with liver cirrhosis and hepatocellular carcinoma treated with cefminox sodium intravenously twice for peritonitis. During the treatments, severe coagulopathy occurred, and the coagulation function quickly recovered after drug withdrawal. The diagnosis and treatment of this patient provides us with ideas for dealing with similar problems in clinical practice in the future. |
| URI | http://hdl.handle.net/20.500.11897/648072 |
| ISSN | 1750-9378 |
| DOI | 10.1186/s13027-022-00446-y |
| Indexed | SCI(E) |
| Appears in Collections: | 北京地坛医院 |
